Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma (ENDURANCE) @NEJMgroup

Uploaded July 2026 | Updated September 2026, 2 weeks ago

Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy.

Read the full phase 3 ENDURANCE trial results and Research Summary at NEJM.org.

#hematology #clinicaltrials #nejm

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma (ENDURANCE)

Prehospital Whole Blood in Traumatic Hemorrhage (SWiFT Trial)

$HFpEF Explained — Living with HFpEF | NEJM In this final episode of a three-part Double Take miniseries on heart failure with preserved ejection fraction (HFpEF) from the New England Journal of Medicine, Lori Hogan and Janice Williams describe what living with HFpEF is like. This patient-focused video explains the condition and offers practical approaches to managing it as a chronic illness. Funding for this Double Take is provided by the Doris Duke Foundation, committed to building a creative, equitable, and sustainable future. #medicaleducation #clinicalmedicine #nejm The New England Journal of Medicine is the world’s leading general medical journal. Continuously published for over 200 years, the Journal publishes peer-reviewed research along with interactive clinical content for physicians, educators, and the global medical community at NEJM.org.$

Doctronic’s Autonomous AI with Dr. Byron Crowe

NEJM Interview: Stacie Dusetzina on a new program that will allow Medicare Part D enrollees to ob...

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts (SCORPIO-PEP)

Highly Pathogenic Avian Influenza A(H5N5) Virus

How Platform Trials Work | NEJM Evidence

Videos in Clinical Medicine: Placement of a Catheter for Acute Peritoneal Dialysis (Overview)